10 slides from Agenus's conference presentation, Jan 21, 2023
Slide 1: Results from a phase 1a/1b study of botensilimab plus balstilimab in MSS CRC
Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC) Authors: Anthony B. El-Khoueiry, MD1, Marwan G. Fakih, MD2, Michael S. Gordo
Slide 2: Active in 'Cold' and IO Refractory Tumors
2 Active in ‘Cold’ and IO Refractory Tumors botensilimab balstilimab Fc-enhanced CTLA-4 Inhibitor PD-1 Inhibitor Active in ‘cold’ and IO refractory tumors1,2 Safety and efficacy analogous to approved anti-PD-1 mAbs5,6 • >300 patients treated across 4 trials • >750 patients treated; 10 ongoing trials
Slide 3: C-800 Study Design: MSS CRC Cohort
3 C-800 Study Design: MSS CRC Cohort NCT03860272: First-in-human trial of botensilimab ± balstilimab in patients with advanced cancer1 Key Eligibility for CRC BOT + BAL • Refractory Metastatic CRC • MSS by local assessment Fc-enhanced CTLA-4 PD-1 • Prior IO allowed 1 or 2 mg/kg Q6W 3 mg/kg Q2W • Tbi
Slide 4: Patient Characteristics
4 Patient Characteristics Characteristic Overall (N=70)* Characteristic Overall (N=70) Age, median (range) 57 (25-83) Prior immunotherapy, n (%) 22 (31) Sex, n (%) Botensilimab dose, n (%) Female 40 (57) 1 mg/kg Q6W + bal (PD-1) Q2W 17 (24) Male 30 (43) 2 mg/kg Q6W + bal (PD-1) Q2W 53 (76) ECOG PS a
7 Overall Survival Efficacy evaluable population, N=70 Overall No Active Liver Mets Active Liver Mets Median, OS (95% CI) NR (10.3-NR) NR (NR-NR) 9.4 (6.1-NR) 12-month, OS (95% CI) 63 (46-76) 81 (66-90) 40 (17-62) PRESENTED BY: Anthony B. El-Khoueiry, MD
Slide 8: Safety Profile
8 Safety Profile All TRAEs of Any Grade in ≥15% of All Patients ALL GRADE GRADE ALL GRADE GRADE n (%) n (%) GRADE 3 4 GRADE 3 4 ANY TRAE 64 (91) 28 (40) 2 (3) SKIN GASTROINTESTINAL Rash 19 (27) 0 0 IM diarrhea/colitis* 30 (43) 14 (20) 1 (1) Pruritus 12 (17) 0 0 Nausea 16 (23) 1 (1) 0 ENDOCRINE CONST
Slide 9: Summary & Future Directions
9 Summary & Future Directions • Botensilimab is a CTLA-4 antibody with enhanced binding to activating Fc receptors enabling innate and adaptive immune activation • Durable objective responses in heavily pre-treated patients with MSS CRC • Manageable safety profile • Favorable overall survival: 12-mo
Slide 10: Abbreviations and Acknowledgements
10 Abbreviations Acknowledgements AE, adverse event IgG, immunoglobulin G ALT, alanine aminotransferase I-O, immunotherapy Agenus Inc. funded and is the sponsor of this APC, antigen presenting cell L, line AST, aspartate aminotransferase LOT, lines of therapy study. mAb, monoclonal antibody bal, bal